These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1362 related articles for article (PubMed ID: 17973267)

  • 1. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
    Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F
    Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
    Cavo M; Tosi P; Zamagni E; Cellini C; Tacchetti P; Patriarca F; Di Raimondo F; Volpe E; Ronconi S; Cangini D; Narni F; Carubelli A; Masini L; Catalano L; Fiacchini M; de Vivo A; Gozzetti A; Lazzaro A; Tura S; Baccarani M
    J Clin Oncol; 2007 Jun; 25(17):2434-41. PubMed ID: 17485707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
    Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
    Cook G; Clark RE; Morris TC; Robertson M; Lucie NP; Anderson S; Paul J; Franklin IM
    Br J Haematol; 2004 Sep; 126(6):792-8. PubMed ID: 15352982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
    Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
    Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
    Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
    Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
    J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
    J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
    J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
    Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.